Does Rallies show Form 4 insider transactions for DYN?

Yes. Rallies tracks DYN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DYN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DYN. It does not provide personalized investment advice.

DYN (Dyne Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Dyne Therapeutics, Inc. Common Stock (DYN) is a publicly traded Healthcare sector company. As of May 20, 2026, DYN trades at $16.57 with a market cap of $2.73B and a P/E ratio of -4.65. DYN moved +4.59% today. Year to date, DYN is -13.95%; over the trailing twelve months it is +36.54%. Its 52-week range spans $6.36 to $36.09. Analyst consensus is strong buy with an average price target of $35.31. Rallies surfaces DYN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DYN stock inside the company?

Recent DYN insider activity includes Friedl-Naderer Johanna sold 228, Kerr Douglas sold 1.56K, Lucera Erick sold 1.45K, Cox John sold 3.31K, and Rhodes Jason P sold 21.93K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DYN Key Metrics

Key financial metrics for DYN
Metric	Value
Price	$16.57
Market Cap	$2.73B
P/E Ratio	-4.65
EPS	$-3.47
Dividend Yield	0.00%
52-Week High	$36.09
52-Week Low	$6.36
Volume	362.68K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-446.21M
Gross Margin	0.00%

Recent DYN Insider Trades

Friedl-Naderer Johanna sold 228 (~$4.19K) on May 13, 2026.
Kerr Douglas sold 1.56K (~$28.72K) on May 13, 2026.
Lucera Erick sold 1.45K (~$26.59K) on May 13, 2026.
Cox John sold 3.31K (~$60.79K) on May 13, 2026.
Rhodes Jason P sold 21.93K (~$398.61K) on May 6, 2026.

Latest DYN News

Dyne Therapeutics Launches 72-Week Phase 3 FORZETTO Trial in 90 Duchenne Muscular Dystrophy Patients — May 20, 2026
Dyne Posts 9.48% Dystrophin Increase, On Track for Q2 2026 BLA Submission — May 11, 2026
Dyne Therapeutics FORCE Platform Achieves 75% MAPT RNA Knockdown in NHP — Apr 27, 2026
Dyne to Present DELIVER, ACHIEVE Data at AMCP, Eyes 2027 DMD and 2028 DM1 Launch — Apr 1, 2026
Dyne Therapeutics Achieves 5.46% Dystrophin Expression, Holds $1.1B Cash for Q2 BLA Plan — Mar 2, 2026

DYN Analyst Consensus

11 analysts cover DYN: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.31.

Common questions about DYN

Who is trading DYN stock inside the company?: Recent DYN insider activity includes Friedl-Naderer Johanna sold 228, Kerr Douglas sold 1.56K, Lucera Erick sold 1.45K, Cox John sold 3.31K, and Rhodes Jason P sold 21.93K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DYN?: Yes. Rallies tracks DYN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DYN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DYN. It does not provide personalized investment advice.